In Stock Cell Lines
Homo sapiens (Human)
Kidney
Adherent
The BRAT1 Knockout HEK293T Cell Line is a CRISPR/Cas9-edited knockout cell line that disrupts the BRAT1 gene, a critical mediator of ATM activation in the DNA damage response. This model enables robust study of genomic integrity pathways, as BRAT1 interacts with BRCA1 and ATM to phosphorylate downstream targets like CHK2 and ??H2AX, enforcing cell cycle checkpoints and DNA repair. HEK293T cells provide a high-expression, easy-to-transfect background for loss-of-function studies. Researchers can employ this knockout line for analyzing ATM signaling, genotoxic drug sensitivities, and neurodevelopmental disorder mechanisms using Western blotting, immunofluorescence, and cell cycle assays.
APOL3 Knockout HAP1 Polyclonal Cells
Cat. No. ARG21869
Human CD19+ B Cells (Negative)
Cat. No. ARP1028
ARL15 Knockout HGC-27 Polyclonal Cells
Cat. No. ARG29612
IPMK Knockout HEK293T Polyclonal Cells
Cat. No. ARG37935
DIO2 Knockout HAP1 Polyclonal Cells
Cat. No. ARG38765
Pig Type II Alveolar Epithelial Cell Medium
Cat. No. ARM0913
The BRAT1 Knockout HEK293T Cell Line is a CRISPR/Cas9-edited knockout cell line designed for precise investigation of DNA damage response and ATM signaling. By disrupting the BRAT1 gene, this model creates a permanent loss-of-function system, allowing researchers to dissect BRAT1-dependent mechanisms in genome stability without the confounding effects of transient gene silencing.
The host cell line, HEK293T, is a human embryonic kidney epithelial line widely adopted for its robust growth and high transfection efficiency. Derived from HEK293, it stably expresses the SV40 large T-antigen, facilitating episomal plasmid replication, and harbors adenovirus type 5 sequences, which together support enhanced protein production and viral packaging.
BRAT1 (BRCA1-associated ATM activator 1) is essential for ATM kinase activation following DNA double-strand breaks or ionizing radiation. It interacts with BRCA1 and ATM, promoting phosphorylation of downstream targets such as H2AX (??H2AX at Ser139), CHK2, and p53, thereby enforcing G2/M cell cycle checkpoint and homologous recombination repair. BRAT1 also coordinates with ATR and the MRE11-RAD50-NBS1 (MRN) sensor complex to transduce DNA damage signals. These post-translational modifications orchestrate cell cycle arrest at G2/M and facilitate DNA repair, underscoring BRAT1’s role in maintaining genomic fidelity.
In the HEK293T context, BRAT1 ablation is expected to impair ATM-dependent phosphorylation cascades, leading to defective DNA repair and compromised cell cycle checkpoints. Because HEK293T cells are aneuploid and possess oncogenic stress from adenoviral transformation, this knockout model provides a distinct platform to investigate synthetic lethal interactions and genotoxic drug responses. It is also relevant for modeling neurodevelopmental pathologies linked to BRAT1 mutations, such as lethal neonatal rigidity and multifocal seizure syndrome (RMFSL).
Representative assays include Western blotting for phosphorylated ATM and its substrates, ??H2AX immunofluorescence to visualize DNA damage foci, flow-cytometric cell cycle analysis, and comet assay for DNA break quantification. Researchers can also perform co-immunoprecipitation to probe ATM-BRAT1 interactions and RT-qPCR to assess DNA repair gene expression, enabling comprehensive pathway dissection. This cell line is a rigorous tool for cancer cell biology, drug sensitivity profiling, and disease modeling. For further details or to request a quote, please contact Ascent Research.
